Click for best price
Postpemic Era NonInsulin Therapies for Diabetes Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Non-Insulin Therapies for Diabetes Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Non-Insulin Therapies for Diabetes industry at home and abroad, estimate the overall market scale of the Non-Insulin Therapies for Diabetes industry and the market share of major countries, Non-Insulin Therapies for Diabetes industry, and study and judge the downstream market demand of Non-Insulin Therapies for Diabetes through systematic research, Analyze the competition pattern of Non-Insulin Therapies for Diabetes, so as to help solve the pain points of various stakeholders in Non-Insulin Therapies for Diabetes industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Non-Insulin Therapies for Diabetes Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Non-Insulin Therapies for Diabetes Market?
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Major Type of Non-Insulin Therapies for Diabetes Covered in XYZResearch report:
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Application Segments Covered in XYZResearch Market
Monitoring
Diagnosis
Treatment
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Non-Insulin Therapies for Diabetes Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
91 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Non-Insulin Therapies for Diabetes Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Non-Insulin Therapies for Diabetes Market by Value
2.2.1 Global Non-Insulin Therapies for Diabetes Revenue by Type
2.2.2 Global Non-Insulin Therapies for Diabetes Market by Value
2.3 Global Non-Insulin Therapies for Diabetes Market by Sales
2.3.1 Global Non-Insulin Therapies for Diabetes Sales by Type
2.3.2 Global Non-Insulin Therapies for Diabetes Market by Sales
3. The Major Driver of Non-Insulin Therapies for Diabetes Industry
3.1 Historical & Forecast Global Non-Insulin Therapies for Diabetes Sales and Revenue (2018-2028)
3.2 Largest Application for Non-Insulin Therapies for Diabetes (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Non-Insulin Therapies for Diabetes Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Non-Insulin Therapies for Diabetes Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Non-Insulin Therapies for Diabetes Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Non-Insulin Therapies for Diabetes Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Non-Insulin Therapies for Diabetes Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Non-Insulin Therapies for Diabetes Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Non-Insulin Therapies for Diabetes Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Non-Insulin Therapies for Diabetes Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Non-Insulin Therapies for Diabetes Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Non-Insulin Therapies for Diabetes Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Non-Insulin Therapies for Diabetes Average Price Trend
13.1 Market Price for Each Type of Non-Insulin Therapies for Diabetes in US (2018-2022)
13.2 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Europe (2018-2022)
13.3 Market Price for Each Type of Non-Insulin Therapies for Diabetes in China (2018-2022)
13.4 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Japan (2018-2022)
13.5 Market Price for Each Type of Non-Insulin Therapies for Diabetes in India (2018-2022)
13.6 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Korea (2018-2022)
13.7 Market Price for Each Type of Non-Insulin Therapies for Diabetes in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Non-Insulin Therapies for Diabetes in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Non-Insulin Therapies for Diabetes Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Non-Insulin Therapies for Diabetes
15. Non-Insulin Therapies for Diabetes Competitive Landscape
15.1 GSK
15.1.1 GSK Company Profiles
15.1.2 GSK Product Introduction
15.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Eli Lilly
15.2.1 Eli Lilly Company Profiles
15.2.2 Eli Lilly Product Introduction
15.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Sumitomo Dainippon Pharma
15.3.1 Sumitomo Dainippon Pharma Company Profiles
15.3.2 Sumitomo Dainippon Pharma Product Introduction
15.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Intarcia Therapeutics
15.4.1 Intarcia Therapeutics Company Profiles
15.4.2 Intarcia Therapeutics Product Introduction
15.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Servier
15.5.1 Servier Company Profiles
15.5.2 Servier Product Introduction
15.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Pfizer
15.6.1 Pfizer Company Profiles
15.6.2 Pfizer Product Introduction
15.6.3 Pfizer Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Merck
15.7.1 Merck Company Profiles
15.7.2 Merck Product Introduction
15.7.3 Merck Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Dong-A Pharmaceutical
15.8.1 Dong-A Pharmaceutical Company Profiles
15.8.2 Dong-A Pharmaceutical Product Introduction
15.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Luye Pharma Group
15.9.1 Luye Pharma Group Company Profiles
15.9.2 Luye Pharma Group Product Introduction
15.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Eurofarma
15.10.1 Eurofarma Company Profiles
15.10.2 Eurofarma Product Introduction
15.10.3 Eurofarma Non-Insulin Therapies for Diabetes Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Geropharm
15.12 Alkem Labs
15.13 SatRx
15.14 Jiangsu Hansoh Pharmaceutical
15.15 Novo Nordisk
15.16 Emisphere
15.17 Uni-Bio Science Group
15.18 Takeda
15.19 3SBio
15.20 Jiangsu Hengrui Medicine
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Non-Insulin Therapies for Diabetes Industry (Volume)
Figure 2. Non-Insulin Therapies for Diabetes Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2022
Figure 5. US Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Non-Insulin Therapies for Diabetes Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Non-Insulin Therapies for Diabetes Revenue, by Type (Million USD) (2018-2028)
Table 4. Non-Insulin Therapies for Diabetes Sales, by Type (K Unit) (2018-2028)
Table 5. Non-Insulin Therapies for Diabetes Sales (K Unit) by Application (2018-2028)
Table 6. Non-Insulin Therapies for Diabetes Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Non-Insulin Therapies for Diabetes Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Non-Insulin Therapies for Diabetes in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. GSK Profiles
Table 61. GSK Non-Insulin Therapies for Diabetes Product Introduction
Table 62. GSK Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. GSK Strategic initiatives
Table 64. Eli Lilly Profiles
Table 65. Eli Lilly Non-Insulin Therapies for Diabetes Product Introduction
Table 66. Eli Lilly Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Eli Lilly Strategic initiatives
Table 68. Sumitomo Dainippon Pharma Profiles
Table 69. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Introduction
Table 70. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Sumitomo Dainippon Pharma Strategic initiatives
Table 72. Intarcia Therapeutics Profiles
Table 73. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Introduction
Table 74. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Intarcia Therapeutics Strategic initiatives
Table 76. Servier Profiles
Table 77. Servier Non-Insulin Therapies for Diabetes Product Introduction
Table 78. Servier Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Servier Strategic initiatives
Table 80. Pfizer Profiles
Table 81. Pfizer Non-Insulin Therapies for Diabetes Product Introduction
Table 82. Pfizer Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Pfizer Strategic initiatives
Table 84. Merck Profiles
Table 85. Merck Non-Insulin Therapies for Diabetes Product Introduction
Table 86. Merck Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Merck Strategic initiatives
Table 88. Dong-A Pharmaceutical Profiles
Table 89. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Introduction
Table 90. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Dong-A Pharmaceutical Strategic initiatives
Table 92. Luye Pharma Group Profiles
Table 93. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Introduction
Table 94. Luye Pharma Group Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Luye Pharma Group Strategic initiatives
Table 97. Eurofarma Profiles
Table 98. Eurofarma Non-Insulin Therapies for Diabetes Product Introduction
Table 99. Eurofarma Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Eurofarma Strategic initiatives
Table 101. Geropharm Profiles
Table 102. Geropharm Non-Insulin Therapies for Diabetes Product Introduction
Table 103. Geropharm Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Geropharm Strategic initiatives
Table 105. Alkem Labs Profiles
Table 106. Alkem Labs Non-Insulin Therapies for Diabetes Product Introduction
Table 107. Alkem Labs Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Alkem Labs Strategic initiatives
Table 109. SatRx Profiles
Table 110. SatRx Non-Insulin Therapies for Diabetes Product Introduction
Table 111. SatRx Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. SatRx Strategic initiatives
Table 113. Jiangsu Hansoh Pharmaceutical Profiles
Table 114. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Introduction
Table 115. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Jiangsu Hansoh Pharmaceutical Strategic initiatives
Table 117. Novo Nordisk Profiles
Table 118. Novo Nordisk Non-Insulin Therapies for Diabetes Product Introduction
Table 119. Novo Nordisk Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. Novo Nordisk Strategic initiatives
Table 121. Emisphere Profiles
Table 122. Emisphere Non-Insulin Therapies for Diabetes Product Introduction
Table 123. Emisphere Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Emisphere Strategic initiatives
Table 125. Uni-Bio Science Group Profiles
Table 126. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Introduction
Table 127. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. Uni-Bio Science Group Strategic initiatives
Table 129. Takeda Profiles
Table 130. Takeda Non-Insulin Therapies for Diabetes Product Introduction
Table 131. Takeda Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 132. Takeda Strategic initiatives
Table 133. 3SBio Profiles
Table 134. 3SBio Non-Insulin Therapies for Diabetes Product Introduction
Table 135. 3SBio Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 136. 3SBio Strategic initiatives
Table 137. Jiangsu Hengrui Medicine Profiles
Table 138. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Introduction
Table 139. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Sales (Unit), Revenue (Million USD) (2018-2022)
Table 140. Jiangsu Hengrui Medicine Strategic initiatives
